Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single arm phase II study to evaluate the efficacy and safety of
fulvestrant as a maintenance hormone therapy after first-line chemotherapy for postmenopausal
HR positive advanced breast cancer.